Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor

Area of Science:

• Immunotherapy
• Oncology
• Cell Biology

Background:

• T-cell malignancies have a poor prognosis due to limited therapeutic options.
• Chimeric antigen receptor (CAR) immunotherapy is effective for B-cell malignancies but challenging for T-cell diseases.
• Targeting CD5 is complicated by its presence on normal T-cells, necessitating alternative effector cells.

Purpose of the Study:

• To develop a novel CAR immunotherapy targeting CD5 for T-cell malignancies.
• To utilize natural killer (NK) cells as effector cells for CD5-targeted CAR therapy.
• To evaluate the efficacy of CD5-targeted CAR-engineered NK cells in preclinical models.

Main Methods:

• Engineered a human NK cell line (NK-92) with a chimeric antigen receptor targeting CD5 (CD5CAR).
• Assessed the anti-tumor activity of CD5CAR NK-92 cells against various T-cell leukemia and lymphoma cell lines and primary tumor cells.
• Evaluated the therapeutic potential in xenograft mouse models of T-cell acute lymphoblastic leukemia (T-ALL).

Main Results:

• CD5CAR NK-92 cells exhibited stable expansion ex vivo.
• Demonstrated potent, specific, and consistent anti-tumor activity against diverse T-cell malignancies.
• Significant inhibition of disease progression was observed in T-ALL xenograft models.

Conclusions:

• CD5CAR-engineered NK cells represent a promising therapeutic strategy for T-cell malignancies.
• This approach offers a viable and complementary therapeutic option to improve patient outcomes.
• NK cell-based CAR therapy provides a potential solution for targeting shared antigens in T-cell cancers.